We narrowed to 10,076 results for: control

#108912-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-ChroME-ST-P2A-H2B-mRuby3 (#108912). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-ChroME-ST-P2A-H2B-mRuby3 plasmid DNA. CAG-driven, Cre-dependent ChroME-ST-P2A-H2B-mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

Hillel Adesnik

Mardinly et al Nat Neurosci. 2018 Apr 30. pii: 10.1038/

Nov. 20, 2018

Academic Institutions and Nonprofits only

#28305-AAV5

Ready-to-use AAV5 particles produced from pAAV-FLEX-ArchT-tdTomato (#28305). In addition to the viral particles, you will also receive purified pAAV-FLEX-ArchT-tdTomato plasmid DNA. CAG-driven Cre-dependent ArchT-tdTomato expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#99039-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#115924

Expression of dCas9 gene under the control of a Ptet promoter in the E. coli chromosome

David Bikard

Cui et al Nat Commun. 2018 May 15;9(1):1912. doi:

March 26, 2019

Academic Institutions and Nonprofits only

#118727

Expression of dCas9 gene under the control of a Ptet promoter in the E. coli chromosome

David Bikard

Rousset et al PLoS Genet. 2018 Nov 7;14(11):e1007749.

April 1, 2019

Academic Institutions and Nonprofits only

#73178

Human sgRNA library in backbone lentiGuide-Puro targeting 19,114 genes and containing 76,441 unique sgRNAs along with 1000 non-targeting controls

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

Feb. 9, 2016

Academic Institutions and Nonprofits only

#73179

Human sgRNA library in backbone lentiCRISPRv2 targeting 19,114 genes and containing 76,441 unique sgRNAs along with 1000 non-targeting controls

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

Feb. 9, 2016

Academic Institutions and Nonprofits only

#73632

Mouse sgRNA library in backbone lentiCRISPRv2 containing 78,637 unique sgRNAs targeting 19,674 genes along with 1000 non-targeting controls

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

Feb. 25, 2016

Academic Institutions and Nonprofits only

#73633

Mouse sgRNA library in backbone lentiGuide-Puro containing 78,637 unique sgRNAs targeting 19,674 genes along with 1000 non-targeting controls

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

Feb. 25, 2016

Academic Institutions and Nonprofits only

#75317

Mouse sgRNA library in backbone lentiCRISPRv2 targeting 713 kinase genes and containing 2,852 unique sgRNAs along with 100 non-targeting controls

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

June 27, 2016

Academic Institutions and Nonprofits only

#75316

Mouse sgRNA library in backbone lentiGuide-Puro targeting 713 kinase genes and containing 2,852 unique sgRNAs along with 100 non-targeting controls

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

June 27, 2016

Academic Institutions and Nonprofits only

#75314

Human sgRNA library in backbone lentiCRISPRv2 targeting 763 kinase genes and containing 3,052 unique sgRNAs along with 100 non-targeting controls

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

June 27, 2016

Academic Institutions and Nonprofits only

#75315

Human sgRNA library in backbone lentiCRISPRv2 targeting 763 kinase genes and containing 3,052 unique sgRNAs along with 100 non-targeting controls

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

June 27, 2016

Academic Institutions and Nonprofits only

#109048-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST (#109048). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST plasmid DNA. Cre-dependent expression of the anion channelrhodopsin GtACR1 fused to ER export signal and targeted to the neuronal soma and proximal dendrites, translated from an internal ribosomal entry site (IRES) following mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

Hillel Adesnik

Mardinly et al Nat Neurosci. 2018 Apr 30. pii: 10.1038/

Feb. 5, 2024

Academic Institutions and Nonprofits only

#99039-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

May 15, 2019

Academic Institutions and Nonprofits only

#200778-AAV8

Ready-to-use AAV8 particles produced from AAV-∆Hapln1 (#200778). In addition to the viral particles, you will also receive purified AAV-∆Hapln1 plasmid DNA. Syn-driven, HAPLN1(delta40-154)-cfGFP expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#200777-AAV8

Ready-to-use AAV8 particles produced from AAV-HAPLN1 (#200777). In addition to the viral particles, you will also receive purified AAV-HAPLN1 plasmid DNA. Syn-driven, HAPLN1-cfGFP expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#200773-AAV8

Ready-to-use AAV8 particles produced from AAV-cfGFP (#200773). In addition to the viral particles, you will also receive purified AAV-cfGFP plasmid DNA. Syn-driven, cysteine-free GFP (cfGFP) expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#185388-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-GRAB_OTmut (#185388). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OTmut plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) control sensor GRAB_OTmut in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

Oct. 21, 2024

Academic Institutions and Nonprofits only